熱門資訊> 正文
RedHill收到总计110万美元的Talicia许可付款
2025-08-18 21:20
- RedHill Biopharma (NASDAQ:RDHL) on Monday announced that it has received its first Talicia ex-U.S. sales milestone, royalties and other payments totaling approximately $1.1 million.
- Talicia is the first-line therapy prescribed by U.S. gastroenterologists for treatment of H. pylori infection.
- RDHL +19.85% premarket to $1.63.
- Source: Press Release
More on RedHill
- Financial information for RedHill
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
